ABAKAVIR I LAMIVUDIN KAK NUKLEOZIDNAYa OSNOVA ANTIRETROVIRUSNOY TERAPII
- Autores: KOZYRINA N.V1, NARSIA R.S1, YURIN O.G1
-
Afiliações:
- Central Research Institute of Epidemiology, Russian Inspectorate for Protection of Consumer Rights and Human Welfare
- Edição: Nº 5 (2014)
- Páginas: 56-60
- Seção: Articles
- URL: https://journals.eco-vector.com/2226-6976/article/view/278105
- ID: 278105
Citar
Texto integral
Acesso aberto
Acesso está concedido
Acesso é pago ou somente para assinantes
Resumo
The review gives data on the safety, tolerability, and efficacy of abacavir (ABC) and lamivudine (3TC), representatives of a reverse transcriptase nucleoside inhibitor group, and the results of clinical trials of the drugs as a basis for antiretroviral therapy. The trials have indicated that ABC/3TC has a virological efficacy that is comparable to that of ZDV/3TC. Some trials have established that ABC/3TC ranks below TDF/FTC in its virological efficacy in patients with the baseline high (more than 100 000 copies/ml) level of HIVRNA. At the same time, ABC/3TC is characterized by its minimal action on the hematopoietic system. As compared to TDF-including regimens, ABC/3TC presents lower risks for osteoporosis and renal tubular dysfunction.
Texto integral
Sobre autores
N. KOZYRINA
Central Research Institute of Epidemiology, Russian Inspectorate for Protection of Consumer Rights and Human Welfare
Email: nad-kozyrina@yandex.ru
Moscow
R. NARSIA
Central Research Institute of Epidemiology, Russian Inspectorate for Protection of Consumer Rights and Human Welfare
Email: narsia@hivrussia.net
Moscow
O. YURIN
Central Research Institute of Epidemiology, Russian Inspectorate for Protection of Consumer Rights and Human Welfare
Email: oleg_gerald@mail.ru
Moscow
Bibliografia
- Доклад ЮНЭЙДС о глобальной эпидемии СПИДа. 2013 г. http://www.unaids.org/en/media/unaids/contentas-sets/documents/epidemiology/2013/gr2013/UNAIDS_ Global_Report_2013_ru.pdf
- Ладная Н.Н., Покровский В.В., Соколова Е.В. ВИЧ-инфекция в России сегодня. Демоскоп Weekly, № 599-600 19 мая - 1 июня 2014 г. http://demoscope.ru/ weekly/2014/0599/tema07.php
- Покровский В.В., Юрин О.Г., Кравченко А.В., Беляева В.В., Канестри В.Г., Афонина Л.Ю. Протоколы диспансерного наблюдения и лечения больных ВИЧ-инфекцией. Эпидемиол. инфекц. болезни. Актуал. вопр. 2013; 6(приложение).
- Guidelines European AIDS Cinical Society. Version 7.0. October 2013.
- Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents, 2014. http://aidsinfo.nih. gov/guidelines
- Hoffmann C., Rockstroh J. HIV 2012/2013. http://hiv-book.com
- Watson M., Sosa N. A Phase III, 48-week, open-label, randomized, multicenter study of the safety and efficacy of the abacavir/lamivudine fixed dose combination tablet administered QD versus abacavir + lamivudine administered BID in combination with a PI or NNRTI in antiretroviral experienced patients (ESS30008). 7th International Congress on Drug Therapy in HIV infection. Glasgow, 2004. Poster P44.
- Mallal S., Nolan D., Witt C., Masel G., Martin A.M., Moore C. et al. Abacavir adverse effects in HIV patients associated with HLA alleles. Lancet 2002; 359: 727-732.
- Norcross M.A., Luo S., Lu L., Boyne M.T., Gomarteli M., Rennels A.D. et al. Abacavir induces loading of novel self-peptides into HLA B*5701 an autoimmune model for HLA-associated drug hypersensitivity. J. Infect. Dis. 2011; 204(8): 1202-1210. http://www.ncbi.nlm.nih.gov/ pubmed/22617051
- Nolan D., Gaudieri S., Mallal S. Frequency HLA B*5701 carriers in the general population of the Earth. J. HIV Ther. 2003; 8(2): 36-41.
- Цыганова Г.М., Буравцова Е.В., Покровский В.В. Опыт использования набора реагентов «АмплиСенс® Геноскрин HLA B*5701-FL» в практической лаборатории. Сборник трудов VIII Всероссийской научно-практической конференции «Молекулярная диагностика 2014». М., 2014; 1: 41.
- Worm S.W., Sabin C., Weber R., Reiss P., El-Sadr W., Dabis F. et al. Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study. J. Infect. Dis. 2010; 201(3): 318-330.
- Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients. AIDS 2008; 22(14): 17-24.
- Trevillyan J.M., Cheng A.C., Hoy J. Abacavir exposure and cardiovascular risk factors in HIV-positive patients with coronary heart disease: a retrospective case-control study. Sex Health. 2013; 10(2): 97-101.
- Xiao D., Andraca-Carrera E., Cooper C., Miele P., Kornegay C., Soukup M., Marcus C. No Association of Abacavir Use with Myocardial Infarction. Findings of an FDA Meta-analysis. J. Acquir. Immune Defic. Syndr. 2012; 61(4): 441-447.
- Satchell C.S., O’Halloran J. A., Cotter A.G., Peace A.J., O’Connor E.F., Tedesco A.F. et al. Increased platelet reactivity in HIV-1-infected patients receiving abacavir-containing antiretroviral therapy. J. Infect. Dis. 2011; 204(8): 1202-1210.
- Antiretroviral Pregnancy Registry Interim Report 1 Jan 1989 - 31 July 2013. http: //www.APRegistry.com.
- Li L., Eron J.J., Ribaudo H., Gulick R.M., Johnson B.A. Evaluating the Effect of Early Versus Late ARV Regimen Change if Failure on an Initial Regimen: Results from the AIDS Clinical Trials Group Study. 2012; A5095. http://www.science. gov/topicpages/a/antiretroviral+arv+regimens.html
- Cuzin L., Pugliese P., Bugnon F., Delpierre C., Cua E., Billaud E. et al. Triple nucleoside reverse transcriptase inhibitor-vs. nonnucleoside reverse transcriptase inhibitor-containing regimens as first-line therapy: efficacy and durability in a prospective cohort of French HIV-infected patients. HIV Med. 2005; 6(6): 388-395.
- Pappa K., Hernandez J. Ha B., Shaefer M., Brothers C., Liao Q. Abacavir/lamivudine (ABC/3TC) shows robust virologic responses in ART-naive patients for baseline (BL) viral loads (VL) of 100,000 c/mL and № 100,000 c/mL by endpoint used in ACTG5202. In: Program and abstracts of the XVII International AIDS Conference. Mexico, 2008; THAB0304.
- DeJesus E., Herrera G., Teofilo E. Castillo S., Bonny T., Thorpe D., Hernandez J. et al. Efficacy and safety of abacavir (ABC) versus zidovudine (ZDV) in antiretroviral therapy naive adults with HIV-1 infection (study CNA30024). In: Abstracts of the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, 2003; H-446.
- Hit Е. Switch from 3TC/ABC to FTC/TDF maintains HIV suppression. In: Program and abstracts of the VI International AIDS Society Conference 6th IAS Conference on HIV Pathogenesis, Treatment and Prevention. Rome, 2011: WELBB03.
- Sax P., Tierney C., Hernandez J., Patel P., Shaefer M., Liao Q. ACTG 5202: shorter time to virologic failure (VF) with abacavir/lamivudine (ABC/3TC) than tenofovir/emtricitabine (TDF/FTC) as part of combination therapy in treatment-naïve subjects with screening HIV RNA >100,000 c/m. In: Program and abstracts of the XVII International AIDS Conference. Mexico, 2008: THAB0303.
- Sax P., Tierney C. Collier A.C., Fischl M.A., Mollan K., Peeples L. et al. Abacavir-lamivudine versus tenofoviremtricitabine for initial HIV-1 therapy. N. Engl. J. Med. 2009; 361(23): 2230-2240. http://www.ncbi.nlm. nih.gov/pubmed/19952143
- Daar E., Tierney C., Fischl M., Collier A.C., Mollan K., Budhathoki C. et al. ACTG 5202: Final results of ABC/3TC or TDF/FTC with either EFV or ATV/r in treatment-naive HIV-infected. In: Program and abstracts of the XVII Conference on Retroviruses and Opportunistic Infections. San Francisco, 2010, 59 LB.
Arquivos suplementares
